Search by year - Any -2024202320222021202020192018201720162015 27 November 2017 Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany Non-regulated information 15 November 2017 Idylla™ Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference Non-regulated information 13 September 2017 Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access Inside information Regulated information 5 September 2017 Idylla™ Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA Non-regulated information 31 August 2017 Strong performance data of proprietary MSI Biomarkers for the Idylla™ MSI Test to be published at ESMO Non-regulated information 12 July 2017 Biocartis’ Idylla™ Instrument and Idylla™ Console exempt from US FDA 510(k) notification requirements Non-regulated information 10 July 2017 Biocartis and A*STAR’s ETPL initiate development of breast cancer assay to guide therapy selection Non-regulated information 13 June 2017 Biocartis launches CE-marked IVD test for lung cancer Non-regulated information 7 June 2017 MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer Non-regulated information 23 May 2017 Biocartis launches CE-marked IVD NRAS test for colorectal cancer Non-regulated information Pagination First page « First Previous page ‹ Previous … Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Next page Next › Last page Last »